Cell adhesion has an essential role in regulating metastasis, and loss of cell adhesion is a classic feature of invasion. There is currently a great deal of interest in the role of adhesion proteins and the antimetastatic protein nm23H1 in the progression of cancer. However, reports on the expression of these proteins in complete hydatidiform moles (CHMs) are limited. In the present study, expression of the adhesion molecules E-cadherin, P-cadherin, CD44, and CD44v6, and the antimetastatic protein nm23H1 was assessed in relation to the invasive potential of CHMs. This is the first report on the expression of these proteins in CHMs. Immunohistochemical assessment was carried out in CHMs (105 cases including 15 cases of invasive moles) and compared with that of gestational age-matched normal placentae (95 cases). The expression of the adhesion proteins ranged from mild to moderate intensity with a general down-regulation in the molar trophoblasts, the down-regulation in CD44 and CD44V6 being highly significant. No relation was, however, noticed with the invasiveness or the persistence of the disease. nm23H1 protein, on the other hand, was significantly down-regulated in the molar trophoblasts with none of the invasive lesions showing intense expression. The study thus suggests down-regulation of adhesion proteins, especially that of CD44 and CD44v6, to be an early step in the transformation to molar placenta with reduced expression of nm23H1 conferring an invasive potential to the trophoblasts.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/j.1048-891x.2004.014316.x | DOI Listing |
Nanotechnology
October 2024
The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Xi'an 710049, People's Republic of China.
Since the sensitivity and accuracy of traditional detection for early gastric cancer diagnosis are still insufficient, it is significant to continuously optimize the optical molecular imaging detection technology based on an endoscopic platform. The signal intensity and stability of traditional chemical fluorescent dyes are low, which hinders the clinical application of molecular imaging detection technology. This work developed a probe based on perovskite quantum dots (PQDs) and peptide ligands.
View Article and Find Full Text PDFFuture Oncol
October 2024
Department of orthopedic, The Second Hospital of Tangshan, No.21, Jianshe North Road, Tangshan 063000, China.
To evaluate the prognostic significance of CD44 variant v6 (CD44v6) and matrix metalloproteinases 2 (MMP2) expression in patients with surgically resected osteosarcoma. CD44v6 and MMP2 expression were immunohistochemically detected in 113 primary osteosarcoma patients at our institute between 2001 and 2019. Both CD44v6 and MMP2 were independent predictors for metastasis-free and overall survival.
View Article and Find Full Text PDFJ Exp Clin Cancer Res
April 2024
Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35128, Padova, Italy.
Background: The intravesical instillation of the paclitaxel-hyaluronan conjugate ONCOFID-P-B™ in patients with bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS; NCT04798703 phase I study), induced 75 and 40% of complete response (CR) after 12 weeks of intensive phase and 12 months of maintenance phase, respectively. The aim of this study was to provide a detailed description of the tumor microenvironment (TME) of ONCOFID-P-B™-treated BCG-unresponsive bladder CIS patients enrolled in the NCT04798703 phase I study, in order to identify predictive biomarkers of response.
Methods: The composition and spatial interactions of tumor-infiltrating immune cells and the expression of the most relevant hyaluronic acid (HA) receptors on cancer cells, were analyzed in biopsies from the 20 patients enrolled in the NCT04798703 phase I study collected before starting ONCOFID-P-B™ therapy (baseline), and after the intensive and the maintenance phases.
Front Immunol
November 2023
Biomedical Research Institute I+12, University Hospital "12 de Octubre", Madrid, Spain.
Targeted therapies are the state of the art in oncology today, and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials, but few of them really change the therapeutic scenario. Difficulties, either to find antigens that are solely expressed in tumors or the generation of good binders to these antigens, represent a major bottleneck. Specialized cellular mechanisms, such as differential splicing and glycosylation processes, are a good source of neo-antigen expression.
View Article and Find Full Text PDFClin Exp Med
December 2023
Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University, Kagawa, Japan.
CD44 and CD44 variant isoforms have been reported as contributing factors to cancer progression. In this study, we aimed to assess whether CD44 and its variant isoforms were correlated with the prognostic factors for distant metastasis in stage I lung adenocarcinomas using tissue microarray and immunohistochemistry. In this single-center retrospective study, we analyzed the data of 490 patients with stage I lung adenocarcinoma resected between 1999 and 2016.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!